Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/4/2025 | $8.00 | Buy | H.C. Wainwright |
4/28/2025 | $7.00 | Outperform | Leerink Partners |
4/1/2025 | $6.00 | Buy | Jefferies |
11/29/2023 | $4.00 | Buy | BTIG Research |
8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
3/31/2022 | Buy → Hold | Needham |
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT). The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that c
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia's common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.03 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Jefferies Global Healthcare Conference will take place June 3-5, 2025, in New York City. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmace
H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00
Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00
Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)